Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform the treatment of autoimmune diseases and cancer by developing allogeneic, iPSC-derived cell therapies.
PRESS RELEASES + EVENTS
view all
January 08, 2026
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology…
December 09, 2025
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology…
About us
We are building an industry-leading, allogeneic, iPSC-derived cell therapy platform for autoimmune diseases and cancer.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
